Suchergebnisse - "Lin, Jianchang"

PubPharm (7)

1

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation

enthalten in: European journal of haematology | 2020

von Dash, A. | Zhang, J. | Shen, L. | +8

2

c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma

enthalten in: European journal of haematology | 2020

von Di Bacco, A. | Bahlis, N. | Munshi, N. | +21

3

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

enthalten in: Blood | 2017

von Avet-Loiseau, H. | Bahlis, N. | Chng, W. | +20

4

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

enthalten in: Haematologica | 2017

von Mateos, M. | Masszi, T. | Grzasko, N. | +15

5

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

enthalten in: British journal of haematology | 2017

von Kumar, S. | Moreau, P. | Hari, P. | +17

6

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2016

von Moreau, P. | Masszi, T. | Grzasko, N. | +124

CommentIn: Nat Rev Clin Oncol. 2016 Jul;13(7):398. - PMID 27217276

7

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

enthalten in: Investigational new drugs | 2015

von Smith, D. | Kalebic, T. | Infante, J. | +14

1
[1]